Short Interest in FibroBiologics, Inc. (NASDAQ:FBLG) Increases By 7.2%

FibroBiologics, Inc. (NASDAQ:FBLG) was the target of a large increase in short interest in November. As of November 15th, there was short interest totalling 2,530,000 shares, an increase of 7.2% from the October 31st total of 2,360,000 shares. Approximately 9.4% of the company’s stock are short sold. Based on an average daily volume of 402,500 shares, the short-interest ratio is currently 6.3 days.

Analyst Ratings Changes

FBLG has been the subject of a number of recent analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $16.00 price target on shares of FibroBiologics in a research report on Wednesday, November 20th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of FibroBiologics in a research report on Wednesday, November 13th. EF Hutton Acquisition Co. I raised shares of FibroBiologics to a “strong-buy” rating in a research report on Wednesday, September 4th. Finally, Maxim Group began coverage on shares of FibroBiologics in a report on Tuesday, September 24th. They issued a “buy” rating and a $12.00 target price on the stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company acquired a new stake in shares of FibroBiologics in the 3rd quarter valued at about $32,000. Jane Street Group LLC bought a new stake in FibroBiologics during the third quarter worth about $37,000. Mercer Global Advisors Inc. ADV acquired a new stake in FibroBiologics during the 2nd quarter worth $51,000. Cahaba Wealth Management Inc. bought a new position in FibroBiologics during the 2nd quarter worth about $73,000. Finally, Symphony Financial Ltd. Co. bought a new position in FibroBiologics during the third quarter worth about $76,000.

FibroBiologics Price Performance

FibroBiologics stock opened at $2.71 on Tuesday. FibroBiologics has a 1 year low of $1.08 and a 1 year high of $55.00. The company’s fifty day moving average price is $2.88 and its 200 day moving average price is $4.32.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.